Yifeng Wang
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Retraction Note: Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.
Journal: Cancer cell international
Published: September 13, 2024
Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.
Journal: Frontiers in oncology
Published: April 03, 2022
GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death.
Journal: Cell death & disease
Published: February 27, 2021
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.
Journal: Frontiers in oncology
Published: September 18, 2020
Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.
Journal: Cancer cell international
Published: December 22, 2019
MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Journal: Journal of cellular and molecular medicine
Published: September 24, 2019
SWAP-70 promotes glioblastoma cellular migration and invasion by regulating the expression of CD44s.
SWAP-70 promotes glioblastoma cellular migration and invasion by regulating the expression of CD44s.
Journal: Cancer cell international
Published: June 20, 2019
Lats1/2-Mediated Alteration of Hippo Signaling Pathway Regulates the Fate of Bone Marrow-Derived Mesenchymal Stem Cells.
Journal: BioMed research international
Published: August 12, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026